Overview

C-Peptide is generated in the regulated secretory pathway of pancreatic beta cells through the processing of proinsulin. When glucose stimulates insulin release, C-Peptide is secreted into the portal circulation in a 1:1 molar ratio with insulin. However, unlike insulin, which is extensively extracted by the liver on first pass (~50%), C-Peptide undergoes negligible hepatic extraction and is cleared primarily by the kidneys with a half-life of approximately 30-35 minutes (compared to ~5 minutes for insulin). This longer half-life and lack of hepatic extraction make C-Peptide a more reliable and stable measure of beta cell secretory function than insulin itself.

The paradigm shift regarding C-Peptide's biological activity began with observations that patients with type 1 diabetes who retained residual C-Peptide secretion experienced fewer microvascular complications than those who were completely C-Peptide-deficient. Subsequent experimental work demonstrated that C-Peptide replacement in type 1 diabetes animal models and in short-term human studies improved nerve conduction velocity, reduced glomerular hyperfiltration, increased nutritive blood flow in skin and muscle, and decreased vascular inflammation. These effects appear to be mediated through a specific cell-surface receptor, with GPR146 proposed as the primary C-Peptide receptor, though this identification remains under active investigation.

The dual nature of C-Peptide — as both a clinical biomarker and a potentially therapeutic molecule — makes it uniquely positioned in diabetes research. Its complete absence in type 1 diabetes (reflecting total beta cell destruction) and its relative preservation or elevation in type 2 diabetes (reflecting insulin resistance with compensatory hypersecretion) underpin its diagnostic utility, while its biological activities offer therapeutic possibilities for addressing the microvascular deficit specific to C-Peptide-deficient states.

Mechanism of Action

C-Peptide exerts its biological effects through several interconnected signaling pathways:

GPR146 Receptor Binding: C-Peptide has been proposed to signal through GPR146, an orphan G protein-coupled receptor identified through ligand-receptor deorphanization studies. Binding activates pertussis toxin-sensitive Gi/Go proteins, leading to downstream signaling cascades. However, this receptor assignment remains debated, and some studies suggest additional or alternative receptor mechanisms.

Na+/K+-ATPase Activation: A well-established downstream effect of C-Peptide signaling is stimulation of Na+/K+-ATPase activity in renal tubular cells, erythrocytes, and nerve fibers. In diabetes, Na+/K+-ATPase activity is impaired, contributing to intracellular sodium accumulation and cellular dysfunction. C-Peptide replacement restores this pump activity, normalizing ion homeostasis.

Endothelial Nitric Oxide Synthase (eNOS) Activation: C-Peptide stimulates eNOS through Ca²+-dependent mechanisms and ERK1/2 MAPK pathway activation, promoting nitric oxide (NO) release from endothelial cells. This enhances microvascular blood flow, which is reduced in diabetes-related microvascular disease.

Anti-Inflammatory Endothelial Effects: C-Peptide attenuates nuclear factor-kappa B (NF-kappaB) activation in endothelial cells stimulated by high glucose or inflammatory cytokines. This reduces expression of adhesion molecules (VCAM-1, P-selectin) and inflammatory chemokines (MCP-1, IL-8), thereby decreasing leukocyte-endothelial interactions and vascular inflammation.

MAPK/ERK Signaling: C-Peptide activates ERK1/2 and p38 MAPK pathways in a pertussis toxin-sensitive manner, mediating proliferative, anti-apoptotic, and transcriptional effects in various cell types including endothelial cells, renal mesangial cells, and neuronal cells.

Reconstitution Calculator

Research

Safety Profile

C-Peptide has demonstrated an excellent safety profile in clinical studies, consistent with its status as an endogenous human peptide. In short-term infusion studies (up to 3 hours) and longer-term subcutaneous administration trials (up to 3 months), no significant adverse effects attributable to C-Peptide have been reported. No immunogenicity, injection site reactions, or systemic toxicity was observed. Importantly, C-Peptide does not cause hypoglycemia — it has no direct insulin-like effects on glucose disposal. The biological effects of C-Peptide appear to be self-limiting, with activity primarily observed in C-Peptide-deficient states (type 1 diabetes) and minimal effects in healthy individuals with normal endogenous C-Peptide levels, suggesting a physiological ceiling effect. Theoretical concerns include the possibility that exogenous C-Peptide could promote vascular smooth muscle proliferation, but this has not been observed at physiological concentrations.

Clinical Research Protocols

• Biomarker assessment (fasting): Fasting C-Peptide measured via immunoassay. Normal range: 0.5-2.0 ng/mL (0.17-0.67 nmol/L). <0.2 nmol/L indicates severe beta cell deficiency.
• Glucagon stimulation test: 1 mg glucagon IV; C-Peptide measured at baseline and 6 minutes post-injection. Peak C-Peptide <0.2 nmol/L confirms severe beta cell failure.
• Mixed-meal tolerance test (MMTT): Standardized liquid meal (Boost/Ensure). C-Peptide measured at 0, 30, 60, 90, 120 minutes. AUC calculation provides integrated measure of beta cell function. Preferred by TrialNet for type 1 diabetes trials.
• Therapeutic infusion protocols (research): IV infusion at 5-30 pmol/kg/min to achieve physiological C-Peptide levels (1-3 nmol/L). Subcutaneous dosing: 600-1800 nmol/day in divided doses.
• Key trials: Wahren et al. neuropathy studies (3-month SC C-Peptide in T1D); Cebix phase 2b trial (ersattra/synthetic C-Peptide for diabetic neuropathy — discontinued 2015 due to lack of efficacy in primary endpoint).
• Duration: Biomarker studies: single time-point to longitudinal (DCCT 6.5-year follow-up). Therapeutic studies: 1 hour infusion to 12 months SC administration.

Subpopulation Research

• Type 1 diabetes: Complete or near-complete absence of C-Peptide. Replacement studies show improvement in nerve function and renal hemodynamics.
• Type 2 diabetes: Normal to elevated C-Peptide (early disease) declining to low levels (advanced disease). Elevated C-Peptide is a marker of insulin resistance and associated with cardiovascular risk.
• LADA (Type 1.5): Intermediate C-Peptide levels. Rate of C-Peptide decline helps differentiate LADA from type 2 diabetes and predicts time to insulin dependence.
• Gestational diabetes: C-Peptide measurement in cord blood reflects fetal beta cell stimulation by maternal hyperglycemia (Pedersen hypothesis).
• Insulinoma: Inappropriately elevated C-Peptide in the setting of hypoglycemia confirms endogenous hyperinsulinism. C-Peptide suppression test (insulin-induced hypoglycemia fails to suppress C-Peptide) is diagnostic.
• Bariatric surgery: Post-surgical C-Peptide changes track beta cell recovery and predict diabetes remission.
• Chronic kidney disease: Elevated C-Peptide due to reduced renal clearance; must be interpreted with caution as a beta cell marker in CKD.

Pharmacokinetic Profile

Ongoing & Future Research

• Long-acting C-Peptide analogs: Development of PEGylated or fatty-acid-conjugated C-Peptide formulations to extend half-life for once-daily or less frequent dosing, overcoming the pharmacokinetic limitations of native C-Peptide.
• C-Peptide receptor definitive identification: Continued research to confirm or revise the GPR146 assignment and characterize the full signaling cascade of C-Peptide at its receptor.
• Neuroprotection beyond neuropathy: Investigation of C-Peptide's effects on central nervous system diabetic complications, including cognitive decline and diabetic encephalopathy.
• Biomarker for beta cell mass: Development of C-Peptide-based algorithms (in combination with imaging and other biomarkers) to estimate residual beta cell mass for clinical decision-making in diabetes.
• C-Peptide in islet transplantation: C-Peptide as a marker of graft function and long-term viability following islet or pancreas transplantation.
• Combination with GLP-1 agonists: Exploring whether C-Peptide supplementation alongside GLP-1 receptor agonists provides additive microvascular benefits in type 1 diabetes.